Keyphrases
Anti-CD20 Antibody
100%
Genetic Strategies
100%
Rituximab
100%
Polymorphism
44%
Complement-dependent Cytotoxicity
33%
FCGR3A
33%
Antibody-dependent Cellular Cytotoxicity
33%
C1QA
33%
Humanized Antibody
22%
Therapy Choice
22%
In Vitro System
22%
Genetic Approach
22%
Immune System
22%
Non-Hodgkin Lymphoma
22%
Lymphoma Patients
22%
Rituximab Therapy
11%
CD20 Antigen
11%
Biosimilar
11%
Malignancy
11%
Cytotoxicity Assay
11%
Antibody Targeting
11%
Genotype
11%
Antibody Response
11%
In Vivo Experiment
11%
Specific Intent
11%
B Cells
11%
Drug Response
11%
Clinical Development
11%
Monoclonal Antibody
11%
Clinical Trials
11%
Improved Survival
11%
In Vitro Response
11%
Clinical Application
11%
Plethora
11%
Survival Rate
11%
Mechanism of Action
11%
Thentest
11%
Response Predictors
11%
Testing Mechanism
11%
Cell Death
11%
Clinical Outcomes
11%
Human Samples
11%
Outcome Prediction
11%
Diffuse Large B-cell Lymphoma (DLBCL)
11%
Neuroscience
Rituximab
100%
CD20 Antibody
100%
In Vitro
70%
In Vivo
60%
Complement Dependent Cytotoxicity
40%
Antibody-Dependent Cell-Mediated Cytotoxicity
30%
Non-Hodgkin Lymphoma
20%
Humanized Antibody
20%
B Cell
20%
CD20 Antigen
10%
Monoclonal Antibody
10%
Cell Death
10%
Immunotherapy
10%
Cytotoxicity Assay
10%
Immunology and Microbiology
CD20 Antibody
100%
Rituximab
100%
Complement Dependent Cytotoxicity
40%
FCGR3A
30%
Antibody-Dependent Cell-Mediated Cytotoxicity
30%
Humanized Antibody
20%
B Cell
20%
Immune System
20%
CD20 Antigen
10%
Biosimilar Agent
10%
Monoclonal Antibody
10%
Survival Rate
10%
Drug Response
10%
Immunotherapy
10%
Antibody Response
10%
Cell Death
10%